Synonyms: MK7762 | TBD09
Compound class:
Synthetic organic
Comment: MK-7762 (also known as TBD09) is the oxazolidinone antibacterial compound claimed in Merck's patent WO2021188606A1 [1]. It is being developed as a treatment for tuberculosis (TB) by Merck and the Bill & Melinda Gates Medical Research Institute.
|
|
References |
1. Crowley BM, Nantermet P, Olsen DB, Suzuki T, Yang L, You L. (2021)
Oxazolidinone compound and methods of use thereof as an antibacterial agent. Patent number: WO2021188606A1. Assignee: Merck Sharp & Dohme Corp. Priority date: 17/03/2021. Publication date: 23/09/2021. |
2. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong L, Mankin AS. (2007)
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell, 26 (3): 393-402. [PMID:17499045] |